What was the primary endpoint demonstrated in the CLL17 trial comparing treatment strategies for frontline CLL?
Superiority of venetoclax-based combinations over ibrutinib monotherapy
Non-inferiority of time-limited venetoclax-based therapy compared to continuous ibrutinib monotherapy
Superiority of MRD-guided therapy over fixed-duration therapy